Last reviewed · How we verify
Talion
Talion is a Small molecule drug developed by Daewoong Pharmaceutical Co. LTD.. It is currently in Phase 1 development.
Talion is a trade name for bepotastine, a small molecule used to treat various conditions such as allergic rhinitis, atopic dermatitis, and pruritus. It is a small molecule with a modality of action that has been studied in clinical trials, including a drug interaction study with erdosteine in healthy adult volunteers.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Talion |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (PHASE3)
- The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (PHASE3)
- A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (PHASE3)
- Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus (PHASE3)
- Repeated Dosing Clinical Trial of HL151 (PHASE1)
- Single Dosing Clinical Trial of HL151 (PHASE1)
- Pharmacokinetics and Safety/Tolerability Profiles of DA-5206 Versus Talion® Under Fasting and Fed States in Healthy Male Subjects (PHASE1)
- Drug Interaction Study Between Erdosteine and Bepotastine Besilate in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Talion CI brief — competitive landscape report
- Talion updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI
Frequently asked questions about Talion
What is Talion?
Who makes Talion?
What development phase is Talion in?
Related
- Manufacturer: Daewoong Pharmaceutical Co. LTD. — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing